The emergence and spread of such TUs and strains are of great concern in terms of food safety, and measures must be implemented to avoid their dissemination in other Gram-negative bacteria and food chains. Seizure detection algorithms (SDAs) based on electroencephalography (EEG) have been described in previous studies, but the imbalanced data distribution of ictal and interictal states continue to pose a technical challenge. This study proposes a novel algorithm to address the imbalanced classification problem and improve seizure detection performance. The proposed algorithm is designed based on hybrid sampling and a cost-sensitive (CS) classifier. Hybrid sampling resamples the imbalanced EEG data at data-level, and the CS classifier, which is used as an algorithm-level tool, reduces the overall misclassification cost of seizure detection. The synthetic minority oversampling technique and undersampling TomekLink technique are combined to reduce the imbalanced ratio between ictal and interictal states while retaining the generalization ability. Finally, CS support vector machine classifies the resampled EEG feature vectors, assigning different cost sensitive parameters to moderate the poor performance resulting from the imbalanced distribution problem. The proposed algorithm improved the average sensitivity and AUC by 46.67% and 0.0482, respectively, compared with the original results without using the imbalanced EEG data processing (IEDP) technique. Experimental results showed that an average sensitivity and AUC of 86.34% and 0.9837, respectively, could be obtained across all cases. Finally, a performance evaluation showed that the proposed algorithm outperformed published methods in terms seizure detection. A fusion algorithm combining data- and algorithm-level methods can achieve high sensitivity and AUC compared with existing IEDP methods. Thus, SDA performance can be improved, enabling their clinical use with EEG-based SMSs. A fusion algorithm combining data- and algorithm-level methods can achieve high sensitivity and AUC compared with existing IEDP methods. Thus, SDA performance can be improved, enabling their clinical use with EEG-based SMSs. Processed electroencephalogram (EEG) is used peri-operatively for monitoring depth of anaesthesia. Because these utilise EEG data, attempts have been made to investigate their use in diagnosing and monitoring seizures. This is important as formal EEG monitoring can be hard to obtain in many critical care environments. We undertook a scoping review of the evidence for using processed EEG (pEEG) from depth of anaesthesia monitors for this indication. Medline, Psych INFO, and Embase were searched for peer-reviewed journals until 20 March 2021. Data and conclusions taken from the study of pEEG in both critical care and peri-operative settings have been included in a qualitative synthesis about the current evidence for the use of pEEG in the detection and monitoring of seizures. Searches yielded 8 observational studies, 1 randomised trial and 15 case reports in which the use of pEEG in critical care and peri-operative medicine was described. Most concerned the Bispectral Index (BIS) device. The majority of observational studies reported the use of BIS for optimisation of burst suppression in patients with refractory status-epilepticus (RSE), or in the comparison of pEEG data with conventional EEG during epileptic activity. Multiple case reports describe the application of pEEG in the presence of disorders of consciousness as a tool for detection of non-convulsive status-epilepticus, finding variable trends in the pEEG output. Processed EEG may be helpful in monitoring pharmacologically induced burst suppression. Despite this, its use in the diagnosing or monitoring seizure activity is controversial and currently not evidenced, with numerous confounding variables that requires systematic assessment in future studies. Processed EEG may be helpful in monitoring pharmacologically induced burst suppression. https://www.selleckchem.com/products/kt-474.html Despite this, its use in the diagnosing or monitoring seizure activity is controversial and currently not evidenced, with numerous confounding variables that requires systematic assessment in future studies.CDKL5 deficiency disorder (CDD) is an independent clinical entity associated with early-onset encephalopathy, which is often considered the type of epileptic encephalopathy with CDKL5 mutation also found in children diagnosed with early-onset seizure (Hanefeld) type of Rett syndrome, epileptic spasms, West syndrome, Lennox-Gastaut syndrome, or autism. Since early seizure onset is a prominent feature, in this study, a cohort of 54 unrelated patients consisting of 26 males and 28 females was selected for CDKL5 screening, with seizures presented before 12 months of age being the only clinical criterion. Five patients were found to have pathogenic or likely pathogenic variants in CDKL5 while 1 was found to have a variant of uncertain significance (p.L522V). Although CDKL5 variants are more frequently identified in female patients, we identified three male and three female patients (11.1 %, 6/54) in this study. Missense variant with unknown inheritance (p.L522V), de novo missense variant (p.E60 K), two de novo splicing (IVS15 + 1G > A, IVS16 + 2 T > A), and one de novo nonsense variant p.W125* were identified using Sanger sequencing. Whole exome analysis approach revealed de novo frameshift variant c.1247_1248delAG in a mosaic form in one of the males. Patient clinical features are reviewed and compared to those previously described in related literature. Variable clinical features were presented in CDKL5 positive patients characterised in this study. In addition to more common features, such as early epileptic seizures, severe intellectual disability, and gross motor impairment, inappropriate laughing/screaming spells and hypotonia appeared at the age of 1 year in all patients, regardless of the type of CDKL5 mutation or sex. All three CDKL5 positive males from our cohort were initially diagnosed with West syndrome, which suggests that the CDKL5 gene mutations are a significant cause of West syndrome phenotype, and also indicate the overlapping characteristics of these two clinical entities.